Published in Lab Business Week, October 9th, 2005
The company intends to use the proceeds to advance its drug pipeline based on the company's unique technology that has the potential to transform the treatment of human genetic diseases. Amicus' lead compound Amigal (migalastat hydrochloride) is in a phase II clinical program for Fabry disease. All of Amicus' current investors participated in the Series C round, which was led by new investor Quaker BioVentures.
"Amicus has truly exciting technology that has breakthrough potential for the treatment of devastating genetic diseases," said Sherrill Neff, managing partner of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week